These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1745376)

  • 1. [Comparison of the efficacy of pantethine, acipimox, and bezafibrate on plasma lipids and index of cardiovascular risk in diabetics with dyslipidemia].
    Tonutti L; Taboga C; Noacco C
    Minerva Med; 1991 Oct; 82(10):657-63. PubMed ID: 1745376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of bezafibrate and acipimox on the lipid pattern and plasma fibrinogen in hyperlipidaemic type 2 (non-insulin-dependent) diabetic patients.
    Niort G; Cassader M; Gambino R; Pagano G
    Diabete Metab; 1992; 18(3):221-8. PubMed ID: 1397477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lowering effect of pantethine on plasma beta-thromboglobulin and lipids in diabetes mellitus.
    Eto M; Watanabe K; Chonan N; Ishii K
    Artery; 1987; 15(1):1-12. PubMed ID: 2963604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Acipimox (Olbetam) as a secondary hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia].
    Yeshurun D; Hamood H; Morad N; Naschitz J
    Harefuah; 2000 Apr; 138(8):650-3, 710. PubMed ID: 10883206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dyslipidemia in diabetes mellitus].
    Niemeijer-Kanters SD; Banga JD; Erkelens DW
    Ned Tijdschr Geneeskd; 2001 Apr; 145(16):769-74. PubMed ID: 11346913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of bezafibrate in the diet of hypertensive patients with dyslipidemia and hyperfibrinogenemia].
    Vázquez-Chávez C; Salinas-Orozco S; Gómez-Díaz RA; Rosso-Juárez MM; Moreno-Vázquez K; Nissen-Torres T; Argüero-Sánchez R
    Rev Invest Clin; 1998; 50(6):491-6. PubMed ID: 10070221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of acipimox and pravastatin in patients with combined hyperlipidemia.
    Fogari R; Marasi G; Vanasia A; Zoppi A; Lusardi P; Preti P
    Int J Clin Pharmacol Ther; 1997 Feb; 35(2):61-4. PubMed ID: 9147709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacologic treatment of dyslipidemias: Analysis of initiation recommendations and drug selection].
    Davidoff P
    Rev Med Chil; 1991 Dec; 119(12):1423-32. PubMed ID: 9723101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Acipimox in primary hyperlipidemias: safety and efficacy evaluated in six months].
    Davidoff P; Ruiz F; Varas MA; García de los Ríos M; Silva MA; González G; Tapia JC
    Rev Med Chil; 1991 Oct; 119(10):1140-6. PubMed ID: 1845208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.
    Cenarro A; Artieda M; Gonzalvo C; Meriño-Ibarra E; Arístegui R; Gañán A; Díaz C; Sol JM; Pocoví M; Civeira F;
    Am Heart J; 2005 Dec; 150(6):1154-62. PubMed ID: 16338252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
    Udawat H; Goyal RK
    Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia--a nuclear magnetic resonance study.
    Ikewaki K; Noma K; Tohyama J; Kido T; Mochizuki S
    Int J Cardiol; 2005 Jun; 101(3):441-7. PubMed ID: 15907413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of long-term treatment with pantethine in patients with dyslipidemia.
    Arsenio L; Bodria P; Magnati G; Strata A; Trovato R
    Clin Ther; 1986; 8(5):537-45. PubMed ID: 3094958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerance of 400 MG bezafibrate in diabetic and hyperlipidaemic patients.
    Lakatos J; Molnár M; Tóth K
    Acta Physiol Hung; 1996; 84(4):433-5. PubMed ID: 9328624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of bezafibrate and gemfibrozil on serum lipoproteins in primary hypercholesterolemia.
    Weisweiler P
    Arzneimittelforschung; 1988 Jul; 38(7):925-7. PubMed ID: 3207437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation.
    Hidalgo L; Zambrana JL; Blanco-Molina A; López-Granados A; Concha M; Casares J; Jiménez-Pérez J; López-Miranda J; Pérez-Jiménez F
    J Heart Lung Transplant; 1995; 14(3):461-7. PubMed ID: 7654731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.